OncoKB New Data Release - December 18, 2025
Contact OncoKB
Data Release v6.0
December 18, 2025
What's New
We are excited to announce that OncoKB™ now includes germline variant annotation on our website! 🎉
This release includes 2649 pathogenic or likely pathogenic germline variants across 109 cancer-associated genes.
Upcoming releases will incorporate therapeutic implications for germline variants and support for germline variant annotation through the API.
To support this expansion, we have introduced a new gene page layout that clearly separates somatic and germline content. See BRCA1 as an example.
For more details on germline variant curation, please refer to our updated SOP, PART II. Germline Variant annotation in OncoKB in v6.0 of the OncoKB SOP.
Release of OncoKB™ SOP v6.0
Transcripts have been updated for the following genes (note, only RefSeq transcripts have changed, not Ensembl transcripts):
View details for updated transcripts
Updated Therapeutic Implications:
Addition of drug(s) associated with a tumor type-specific leveled alteration(s) currently in OncoKB™ (without changing the alteration's highest level of evidence)
Level 1: Addition of Sevabertinib to ERBB2 Tyrosine Kinase Domain Activation Mutations in non-small cell lung cancer based on FDA approval of sevabertinib for patients with locally advanced or metastatic, non-squamous non-small cell lung cancer whose tumors have ERBB2 tyrosine kinase domain activating mutations (PMID: 41104928)
ERBB2 Tyrosine Kinase Domain Activation Mutations include the following: L726F/I, T733I, L768S, L755A/P/S/W, I767M, D769H/Y, V773L, G776S/V, V777L/M, V794M, T798M, D808N, G815R, D821N, L841V, V842I, L866M, L869R, 770_831ins
Level 1 sensitivity-associated therapeutics currently in OncoKB™ for ERBB2 Tyrosine Kinase Domain Activating Mutations in non-small cell lung cancer: Trastuzumab Deruxtecan, Zongertinib
Gene Curation:
Addition of 18 new genes:
ALDH1A3 ANK1 APOBEC3B ATG5 BABAM2 BCL9L BIRC5 BRD2 BRD9 CCAR1 CCNB1IP1 CEP43 CHCHD7 CILK1 CLIP1 KDSR LASP1 MLF1
We're Here to Help
As always, don’t hesitate to reach out if you have comments, questions or suggestions. We love to hear from you. You can reach us at con...@oncokb.org
